Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Beginning Cash Balance (2022 - 2023)

Bioregenx has reported Beginning Cash Balance over the past 2 years, most recently at $190891.0 for Q4 2023.

For Q4 2023, Beginning Cash Balance rose 27170.14% year-over-year to $190891.0; the TTM value through Mar 2024 reached $18001.0, down 37.86%, while the annual FY2023 figure was $191001.0, 27185.86% up from the prior year.
Beginning Cash Balance for Q4 2023 was $190891.0 at Bioregenx, up from -$172890.0 in the prior quarter.
Over five years, Beginning Cash Balance peaked at $190891.0 in Q4 2023 and troughed at -$172890.0 in Q2 2023.